Evidence map›Paper›PMID 42035080›Full record

ArticleWorld journal of surgical oncology2026

REBACIN

Jie-Jie Li, Su-Su Yang, Kang-Jia Chen, Li-Shuai Jiang, Ya-Xing Fang, Chun-Li Liu, Sheng Wang, Chun Ye, Liang-Feng Yao, Yu-Qi Chen and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jie-Jie Li *Department of Gynecology, Children's Medical Center of Anhui Medical University, Anhui Maternity and Child Healthcare Hospital, Hefei, Anhui, China.
Su-Su Yang *Department of Gynecology and Obstetrics, Anhui Medical University, Hefei, Anhui, China.
Kang-Jia Chen *Department of Gynecology, Children's Medical Center of Anhui Medical University, Anhui Maternity and Child Healthcare Hospital, Hefei, Anhui, China.
Li-Shuai Jiang *Department of Gynecology, Children's Medical Center of Anhui Medical University, Anhui Maternity and Child Healthcare Hospital, Hefei, Anhui, China.
Ya-Xing Fang *Department of Gynecology and Obstetrics, Anhui Medical University, Hefei, Anhui, China.
Chun-Li Liu *Department of Gynecology Clinic for Cervical and Pelvic Floor Disorders, City Central Hospital, Tai'an, Tai'an, Shandong, China.
Sheng WangKey Laboratory of Protein Engineering and Drug Development of Hainan, Haikou, China.
Chun YeDepartment of Cervical Disease Diagnosis and Treatment Center, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Liang-Feng YaoDepartment of Obstetrics and Gynecology, Zhangzhou Municipal Hospital, Zhangzhou, Fujian, China.
Yu-Qi ChenDepartment of Obstetrics and Gynecology, Nan'an Hospital, Quanzhou, Quanzhou, Fujian Province, Fujian, China.
Xiao LiDepartment of Obstetrics and Gynecology, Mianyang City Central Hospital, Mianyang, Sichuan, China.
Jing JiangDepartment of Gynecology, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
Feng-Ming HeDepartment of Gynecology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Yu-Li LingKey Laboratory of Protein Engineering and Drug Development of Hainan, Haikou, China.
Shu-Guang ZhouDepartment of Gynecology, Children's Medical Center of Anhui Medical University, Anhui Maternity and Child Healthcare Hospital, Hefei, Anhui, China. zhoushuguang@ahmu.edu.cn.

Funding

Fuyang Health Research Project FYZC2024 - 038The Applied Medicine Research Project of Hefei Health Commission HWKJ2019-172-14the Natural Science Foundation of Higher Education Institutions of Anhui Province KJ2021A0352The Research Fund Project of Anhui Medical University 2020xkj236
6 · The paper itself

Abstract

objectiveTo evaluate the efficacy of REBACIN® as a non-invasive treatment for persistent high-risk HPV (HR-HPV) clearance compared with interferon and no treatment, identify optimal cutoff values for HPV E6/E7 mRNA/DNA assays, analyze clinical predictors, and validate REBACIN® as a safe alternative to invasive interventions for cervical cancer prevention.

methodsAccording to the predefined inclusion and exclusion criteria, eligible patients were randomly selected and enrolled after obtaining their informed consent. Patients were allocated to three groups: the REBACIN group (received a course of intravaginal REBACIN administration), the recombinant human interferon α-2b group (received recombinant human interferon α-2b treatment), and the control group (received no treatment). After drug discontinuation, follow-up was conducted for all participants across the three groups.

resultsIn the HPV E6/E7 mRNA and HPV-DNA testing cohorts, the clearance rates in the REBACIN

conclusionThis study suggests that REBACIN® may represent a non-invasive treatment option, providing a new option for the clinical treatment of persistent HR-HPV infections to prevent cervical cancer.

Indexed as

Antiviral AgentsHuman Papillomavirus VirusesPapillomavirus InfectionsPersistent InfectionUterine Cervical NeoplasmsAdultDNA, ViralFemaleFollow-Up StudiesHumansInterferon alpha-2Middle AgedOncogene Proteins, ViralPrognosisProspective StudiesAntiviral AgentsDNA, ViralInterferon alpha-2Oncogene Proteins, ViralClearance rateEfficacy RateHigh-risk HPVREBACIN®Recombinant human interferon α-2b

Identifiers

PMID42035080
PMCPMC13348635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.